



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

GSHISHIMA@FULBRIGHT.COM DIRECT DIAL: (512) 536-3081 TELEPHONE:

(512) 474-5201

FACSIMILE:

(512) 536-4598

September 8, 2004

CERTIFICATE OF MAILING 37 C.F.R 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

September 8, 2004

Date

Gina N. Shishima

MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 SEP 1 4 2004

TECH CENTER 160012900

RE:

U.S. Patent Application No. 09/660,568 entitled "DIAGNOSIS OF DISEASE STATE USING

MRNA PROFILES IN PERIPHERAL LEUKOCYTES" - David Ralph et al.

Our reference: UROC:014USD1

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, references A8, B3-B6, and C72-C84, and copy of foreign communication.

No fees are believed to be due in connection with the filing of this Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UROC:014USD1.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Ğina N. Shishima

Reg. No. 45,104

GNS/kmv

Encl.: as noted

25450468.1





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David Ralph et al.

Serial No.: 09/660,568

Filed: September 11, 2000

For: DIAGNOSIS OF DISEASE STATE USING MRNA PROFILES IN PERIPHERAL

LEUKOCYTES

Group Art Unit: 1635

SEP 1 4 2004

Examiner: Sean McGarry

iecheenen 160men

Atty. Dkt. No.: UROC:014USD1

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:, MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

September 8, 2004

Date

Qina N. Shishima

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to

patentability as defined in 37 C.F.R. § 1.56(b).

This application is a divisional application of Serial No. 09/046,894, filed March 24,

1998 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule

37 C.F.R. § 1.98(d) only copies of those documents not previously cited and submitted to the

Patent and Trademark Office in prior application Serial No. 09/046,894 are enclosed for the

convenience of the Examiner.

In accordance with 37 C.F.R § 1.97(e)(1), Applicants hereby certify that each item of

information contained in this Supplemental Information Disclosure Statement was first cited in

any communication from a foreign patent office in a counterpart foreign application not more

than three months prior to the filing of the present statement, as evidenced by the date of the

enclosed search report.

Applicants respectfully request that the listed documents be made of record in the present

case.

Respectfully submitted,

Gina N. Shishima

Reg. No. 45,104

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

September 8, 2004

25450465.1

Form PTO-1449 (modified)

jst of Patents and Publications for Applicant's

Serial No. Atty. Docket No. UROC:014USD1 09/660,568 **Applicants**

Information Disclosure Statement

TECH CENTER 1600/2900 Group:

(Use several sheets if necessary)

Filing Date: 1635 September 11, 2000

David Ralph et al.

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	See Page 1	See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.
	A8	5,543,296	8/06/96	Sobol et al.	435	6	12/16/94

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	В3	WO 96/17080	6/06/96	PCT			English
	B4	WO 96/21671	7/18/96	PCT			English
	B5	WO 98/10098	3/12/98	PCT			English
	В6	WO 99/15658	4/01/99	PCT			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C72	Berghella et al., "Prognostic significance of immunological evaluation in colorectal cancer," Cancer Biotherapy & Radiopharmaceuticals, 11(6):355-361, 1996.
	C73	Brew et al., "Detection of interleukin-8 mRNA and protein in human colorectal carcinoma cells," European J. Cancer, 32A(12):2142-2147, 1996.
	C74	Edmonds et al., "Elongation factor 1α is an overexpressed actin binding protein in metastatic rat mammary adenocarcinoma," J. Cell Science, 109:2705-2714, 1996.
	C75	Ferrer et al., "Cytokine regulation of angiogenesis factors in human prostate cancer," Proceedings of the American Urological Association, 135:163, 1996.
	C76	Greene et al., "Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cels implanted in nude mice using an in situ messenger RNA hybridization technique," American Journal of Pathology, 150(5):1571-1582, 1997.
	C77	Gutman et al., "Regulation of interleukin-8 expression in human melanoma cells by the organ environment,"

25450441.1

Date Considered: Examiner:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (modified)		Atty. Docket No. Serial No. UROC:014USD1 09/660,568		
List of Patents and Publications for Applicant's		Applicants David Ralph et al.		
INFORMATION DISCLOSURE S	TATEMENT			
(Use several sheets if necessary)		Date: Group: 1635		
U.S. Patent Documents Foreign F		ocuments Other Art		
See Page 1		1 See Page 1		

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C78	Heller et al., "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays," Proc. Natl. Acad. Sci., USA, 94:2150-2155, 1997.
	C79	Isaacs, "Molecular markers for prostate cancer metastasis: developing diagnostic methods for predicting the aggressiveness of prostate cancer," American J. Pathology, 150(5):1511-1521, 1997.
	C80	Nagase et al., "Prediction of the coding sequences of unidentified human genes. VI. The coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of cDNA clones from cell line KG-1 and brain," DNA Research, 3:321-329, 1996.
	C81	Pencil et al., "Candidate metastasis-associated genes of the rat 13762NF mammary adenocarcinoma," Breast Cancer Research and Treatment, 25:165-174, 1993.
	C82	Ueda et al., "Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis," J. Gastroenterol., 29:423-429, 1994.
	C83	Wellstein et al., "Growth factors as targets in tumor therapy," International J Pharmacology, 33:35-47, 1995.
	C84	Zhang and Zhang, "Rapid identification of differentially expressed RNA transcripts in apoptotic T lymphocytes," J. Immunological Methods, 195:113-123, 1996.

25450441.1

Examiner: Date Considered:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.